EUCTR2010-022681-27-CZ进行中（未招募）1 期
Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia
niversity Hospital Brno0 个研究点目标入组 30 人开始时间: 2010年9月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet the following criteria:
- •a)Male or female previously treated patients with B-cell CLL requiring therapy according to the revised NCI criteria (including CLL patients with immune-mediated hemolysis or thrombocytopenia). Prior therapy with rituximab (monotherapy or combination therapy) is not necessary.
- •b)Flow cytometry confirmation of CLL immunophenotype with CD5, CD19, CD20, CD23, CD79b, and surface Ig at screening.
- •c)Disease recurrence (or refractority) after at least one fludarabine-containing regimen, or after at least two previous chemotherapy regimens without fludarabine; and/or poor marrow reserve not allowing chemotherapy administration (Absolute Neutrophil Count < 1.0 x 109/L and/or Absolute Platelet Count < 50 x 109/L).
- •d)Age = 18 years
- •e)Signed written informed consent
- •f)Life expectancy > 3 months
- •g)ECOG performance status = 2
- •h)CT scan performed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting any of the following criteria must not be enrolled in an ofatumumab study:
- •a)Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- •b)Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study
- •c)Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.
- •d)Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy.
- •e)Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C
- •f)History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
- •g)Known HIV positive
- •h)Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure (NYHA III-IV), and arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities.
- •i)Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the investigator may represent a risk for the patient.
- •j)Positive serology for Hepatitis B (HBV) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HBV DNA test will be performed and if positive the subject will be excluded. See section 10.3.2.1 Hepatitis B screening.
- •k)Positive serology for hepatitis C (HCV) defined as a positive test for anti-HCVAb, in which case reflexively perform a HCV RIBA immunoblot assay on the same sample to confirm the result
- •l)Screening laboratory values:
- •i.creatinine >2.0 times upper normal limit
- •ii.total bilirubin >1.5 times upper normal limit (unless due to CLL involvement of liver or a known history of Gilbert’s disease)
- •iii.ALT >2.5 times upper normal limit (unless due to disease involvement of liver)
- •iv.alkaline phosphatase >2.5 times upper normal limit (unless due to disease involvement of the liver or bone marrow)
- •m)Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test at screening.
- •n)Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as intrauterine device, double barrier method or total abstinence. Oral contraceptive pills are not permitted (dexamethasone induces CYP3A4, therefore oral hormonal birth control may be more rapidly or extensively metabolized and, therefore, less effective).
- •o)Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.
研究者
相似试验
已完成
2 期
Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT01310101Brno University Hospital33
进行中（未招募）
1 期
Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210) - CLL210 (OfaDexRev)Chronic lymphocytic leukaemia / Small Lymphocytic LymphomaMedDRA version: 18.0 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 100000004864MedDRA version: 18.0 Level: LLT Classification code 10041152 Term: Small lymphocytic lymphoma, consistent with CLL (Working Formulation) System Organ Class: 100000004864EUCTR2010-019575-29-GBniversity of Liverpool64
进行中（未招募）
不适用
Phase I/II trial of dexamethasone, ofatumumab and bendamustine [Treanda] (DOT) as first-line treatment of mantle-cell lymphoma (MCL) in the elderly - DOT in elderly MCL patientsMantle-cell lymphoma (MCL)MedDRA version: 9.1Level: LLTClassification code 10061275EUCTR2009-015909-39-ITISTITUTO NAZIONALE PER LA CURA TUMORI
招募中
2 期
Evaluation of the effect of adding dexamethasone to lidocaine in digital blockIRCT20110103005536N9Artesh University of Medical Sciences60
已完成
3 期
The effect of two methods of using dexamethasone in reducing pain after root canal treatmentPulpitisIRCT20240109060657N1Boushehr University of Medical Sciences96